Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.60 |
| ▸ | CA1 | P00915 | 10/20 | 0.40 |
| ▸ | CA2 | P00918 | 10/20 | 0.40 |
| ▸ | CA9 | Q16790 | 10/20 | 0.40 |
| ▸ | CA12 | O43570 | 9/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288533 | 0.85 | MMP13 (0.57) | MMP13 | |
| SCHEMBL6288447 | 0.83 | MMP13 (0.58) | MMP13 | |
| SCHEMBL6287118 | 0.83 | MMP13 (0.52) | MMP13CA1CA2CA9CA12 | |
| SCHEMBL6288668 | 0.82 | MMP13 (0.45) | MMP13 | |
| SCHEMBL6291902 | 0.82 | MMP13 (0.58) | MMP13 | |
| SCHEMBL6288444 | 0.81 | MMP13 (0.46) | MMP13 | |
| SCHEMBL5697120 | 0.80 | MMP13 (0.69) | MMP13CA1CA2CA9CA12 | |
| SCHEMBL6291472 | 0.80 | MMP13 (0.46) | MMP13 | |
| SCHEMBL6291414 | 0.79 | MMP13 (0.61) | MMP13 | |
| SCHEMBL6288453 | 0.79 | L3MBTL1 (0.49) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014378-A1 | 3-ISOQUINOLINONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6974822-B2 | 3-isoquinolinone derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014378-A1 | 3-ISOQUINOLINONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | MMP13 5/4885CA1 1202/4885CA2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.